VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.

​

​

 

 

 

Aiming to submit NDA in 2020-2021.

VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.

​

​

 

 

 

Aiming to submit NDA in 2020-2021.

VTS-K: Ketamine + VTS Aspirin for Postoperative Pain

VTS-K: Ketamine + VTS Aspirin for Postoperative Pain

Vitalis

  • About Us

  • VTS-Platform

  • What is Flush?

  • Pipeline

  • Media

  • Contact Us

  • More

    Aiming to Improve Patients' Lives in Multiple Sclerosis, Post-op Pain (Non-opioid), and Dyslipidemia

    LEARN MORE

    Vitalis is committed to improving the lives of patients

    This mission provides the focus for everything we do, from early research to product development.

     

    Our research is focused on changing the paradigm of patient treatment with efforts to discover innovative uses of existing medications.

    ​

    Leveraging its VTS-Aspirin platform, Vitalis may help millions of patients each year, starting in three major treatment areas.

    VTS-72: Multiple Sclerosis
    VTS-K: Post-op Pain
    VTS-63: Dyslipidemia
    • Vitalis Pharmaceuticals Twitter
    • Vitalis Pharmaceuticals LinkedIn

    © 2019 Vitalis, LLC

    All Rights Reserved.

    New York, NY

    admin@vitalispharma.com

     

    ​

    Cookie Policy

    Terms of Use

    Privacy Policy

    Media